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a  b  s  t  r  a  c  t
Background:  Burning  mouth  syndrome  (BMS)  is  a chronic  pain  condition  with  indefinite  cure,  predomi-
nantly  affecting  post-menopausal  women.  The  aim  of  this  study  was to systematically  review  the  efficacy
of low  level  laser therapy  in the treatment  of  burning  mouth  syndrome  (BMS).
Methods:  PubMed,  Embase  and  Scopus  were  searched  from  date  of  inception  till  and  including  October
2016  using  various  combinations  of  the  following  keywords:  burning  mouth  syndrome,  BMS,  stom-
atodynia,  laser  therapy,  laser  treatment  and  phototherapy.  The  inclusion  criteria  were:  Prospective,
retrospective  and  case  series  studies.  Letter  to editors,  reviews,  experimental  studies,  studies  that  were
not published  in  English,  theses,  monographs,  and  abstracts  presented  in scientific  events  were  excluded.
Due to heterogeneity  of  data  no  statistical  analyses  were  performed.
Results:  Ten  clinical  studies  fulfilled  the  eligibility  criteria,  five  of which  were  randomized  clinical  tri-
als.  In  these  studies,  the laser  wavelengths,  power  output  and  duration  of  irradiation  ranged  between
630–980  nm,  20–300  mW,  10  s–15  min,  respectively.  Most  of  studies  reported  laser  to  be an  effective
therapy  strategy  for management  of  BMS.
Conclusion:  Majority  of  the  studies  showed  that  laser  therapy  seemed  to  be effective  in reducing  pain  in
BMS patients.  However,  due  to the  varied  methodologies  and  substantial  variations  in  laser  parameters
among  these  studies,  more  clinical  trials  are required  to ascertain  the efficacy  of laser  for  treating  BMS.
© 2016  Elsevier  B.V.  All  rights  reserved.
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. Introduction
Burning mouth syndrome (BMS) (synonyms: glossodynia, glos-
opyrosis, stomatopyrosis, stomatodynia, and dysesthesia [1] is
 chronic pain condition, which predominantly affects post-
enopausal women in their 5th to 7th decade [2]. According to the
nternational Headache Society, burning mouth syndrome (BMS)
s defined as an intraoral burning sensation for which no medi-
al or dental cause can be identified [3]. In addition to burning
ensation in the mouth, patients with BMS  usually complain of
nremitting mucosal pain, xerostomia and dysguesia [1,4]. The
nterior two thirds of the tongue is the most frequently affected
ite, although any site of oral mucosa can be affected [1,4]. BMS  is a
elatively common condition with an estimated prevalence rate of
.6% in the general population, and up to 12–18% among postmen-
usal women [1,4–7]. It is typically a disease of the middle-aged
nd elderly women, with a female-male ratio of 7-1 [1]. Although
he exact etiopathogenesis remains unclear, recent evidence sug-
est that BMS  is neuropathogenic in nature, and neurophysiological
tudies indicates the possibility of a dysfunction at the peripheral
nd central reflex arc path and the processing of cortical excitation
8,9]. There is no specific therapy for BMS  as yet and the treatment
s solely aimed to alleviate symptoms. Medications that have been
sed for treatment BMS  include antidepressants, antipsychotics,
ntiepileptics, analgesics, and topical capsaicin [10,11]; vitamin
 complex and dietary supplements (such as zinc and folic acid)
ormonal replacement (conjugated estrogens), have also been pro-
osed as potential therapeutic strategies [2,10]. Despite the large
ariety of medication and other approaches proposed for BMS  man-
gement, the treatment has been unsatisfactory and as yet there is
o a definite cure.
The use of Low-level laser therapy (LLLT), also known as photo-
iomodulation or cold laser therapy, in treatment of pain induced
y BMS  has been of great interest in the recent years. LLLT is
on- drug, non-invasive clinical application which has poten-
ial analgesics, anti-inflammatory and biostimulaing effects, with
inimum adverse effects [12,13]. Low-level energy laser showed
everal effects that can be helpful in reducing the burning sensation.
hese include increasing in synthesis and release of serotonins and
-endorphins, blocking the depolarization of c-fiber and decreasing
radykinin secretion [14–18]. A number of studies have assessed
he efficacy of laser in treatment of BMS  [8,14–22]. Arbabi Kalati
t al. [19] reported a significantly better improvement in BMS
ymptoms and quality of life among laser treated patients as com-
ared to placebo group. Similarly, Spanemberg et al. [8] reported
 significantly better improvement in BMS  symptoms among
nfrared laser treated patients than control placebo group. On the
ther hand, Pezlj-Ribaric [21] did not find differences in the symp-
oms of BMS  in laser treated patients when compared to placebo
ontrol. Additionally, Sugaya et al. [22] evaluate the efficiency of
LLT in treatment of BMS  and reported that both laser as well as
lacebo showed similar effects on the symptoms, and that the laser
roup showed a statistically better improvement only at the fourth
heckpoint.There seems to be some controversy on the efficacy of laser ther-
py in management of BMS. Therefore, the aim of this study was  to
ystematically evaluate the evidence on the efficacy of laser therapy
n the management of BMS. . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . .  .  . . . .  .  . .  . . .  .  .  .  . .  . . . . .  . . . . .  .  .  .  .  . .  .  .  .  .  .  . 193
2. Materials and methods
2.1. Focused question
According to the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) guidelines, specific question
was framed. The concerned focused question was “Is laser therapy
effective in treatment of BMS?”
2.2. Eligibility criteria
The eligibility criteria for this systematic review were: Prospec-
tive, retrospective and case series studies, that assessed the efficacy
of Laser in management of BMS. Additionally, studies were included
only if they excluded patients with oral mucosal lesions or abnor-
mal  laboratory findings, such as anemia and vitamin deficiencies.
Case reports, animal or in-vitro studies, letter to the editor, mono-
graphs, conference papers, reviews, unpublished data and studies
published in a language other than English were excluded from the
study.
2.3. Literature search
A literature search was conducted on Medline/PUBMED, Embase
and Scopus to identify all relevant articles published in English
from date of inception up to and including October 2016. Vari-
ous keywords were used in different combinations: burning mouth
syndrome, BMS, stomatodynia, Laser therapy, Laser treatment,
phototherapy, low level laser therapy, low intensity laser therapy,
infrared laser, low energy laser therapy.
Initially, titles and abstracts of all studies identified through the
search strategies, described above, were screened by two  authors
(SA, NA), and irrelevant studies were excluded. Full-texts of all rele-
vant studies (judged by title and abstract) were read and evaluated
independently by the two  authors for eligibility criteria. Addi-
tionally, Additionally, to locate any potential unidentified studies,
we manually searched bibliographies and reference lists of the
included studies. Moreover, a search in some journals highly likely
to contain studies relevant to the review topic was done. These jour-
nals include the Journal of photomedicine Laser Surgery, journal of
biomedical optics, Lasers Medical Sciences, Photomedical & photo-
biological Sciences. The initial aim was to undergo meta-analysis
but due to inconsistency of data and heterogeneity of the included
studies, we did not perform statistical analysis [23].
2.4. Assessment of quality
The quality of Randomized Clinical trials was  assessed by two
independent authors following 5-point “Jadad” checklist [24], as
illustrated in Table 1.
2.5. Data extractionThe following data were extracted by two  independent authors
using a standardized data collection form: authors and year of
study, study design, gender, number of patients, age range, study
protocol, site of laser application, methods of pain assessment, laser
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Table  1
Quality assessment of the included RCT studies according to Jadad scale.
Randomized Random described Patient blind Observer blind Withdrawals handled Total score
Arbabi-Kalati et al. [19] 1 0 1 1 1 4
Spannenberg et al. [8] 1 0 1 0 1 3
Arduino et al. [14] 1 1 0 1 1 4
Pezlj-Ribaric et al. [21] 1 0 1 0 1 3















Fig. 1. Flow ch
ype, dose, application time, frequency or number of sessions per
eek, follow up and pain outcomes.
. Results
.1. Study selection
The study search process is summarized Fig. 1. The initial search
ielded a total of 25 studies, 10 of which did not fulfill the inclusion
riteria and therefore excluded. Another 5 studies did not abide to
ligibility criteria and were thus excluded. The remaining 10 studies
8,14–22] were reviewed and processed for data extraction.
.2. General characteristics of included studies
Among the included studies, 5 were randomized clinical stud-
es [8,14,19,21,22], 3 uncontrolled clinical studies [16,17,20] and
 were case series [15,18]. Of the 5 RCT studies, 4 [8,19,21,22]
ompared the efficacy of laser with placebo, while one study [14]
ompared the efficacy of laser therapy to that of clonazepam. methodology.
Five studies were conducted in Brazil [8,15,16,20,22], two in
Italy [14,17], one in Croatia [21], one in Taiwan [18] and one in Iran
[19]. Study design, sample size, type of intervention and control of
each study were analyzed and summarized according to the CON-
SORT protocol (Table 2). The total number of subjects involved in
the intervention ranged between 10 and 78 patients. In all the stud-
ies, more than two  thirds of the subjects were females. Nine studies
[8,14,15,18–22] reported the mean age of study participants, which
was between 47.2 and 68.5 years with a range of 18–87 years.
All 10 studies [8,14–22] evaluated the effect of laser therapy
in reducing pain in BMS  patients. Three studies evaluated both
pain and quality of life related to oral health among BMS  patients
[8,14,19] using Oral Health Impact Profile (OHIP), one study [14]
assessed levels of anxiety and depression, and one study evaluated
levels of saliva pro-inflammatory cytokines [21]. Nine studies (8,
14–16, 18–22) assessed pain by Visual Analogue Scale (VAS) while
one study [17] assessed pain by Numerical Rating Scale (NRS) and in
one study [14] present pain intensity (PPI) was also used. Six stud-
ies reported post-operative follow up period, which ranged from 6
weeks up to 12 months [8,14–16,18,22].
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3.3. Laser related characteristics of included studies
In all 10 studies [8,14–22] diode laser was used with wave-
lengths ranging from 630 to 980 nanometer (nm) and power output
ranging from 20 to 300 MW (Table 3). Six studies [8,15,16,19,20,22]
reported the dose of radiation which ranged between 0.4–6 Joul
(J). In nine studies [8,14–18,20–22] fluence energy of laser was
reported that ranged from 0.53 up to 176 Jouls per square centime-
ter (J/cm2). The power density was reported by 5 studies which
ranged between 1 and 4 wat  per square centimeter (W/CM2). The
reported exposure time was  between 10 s to 15 min. Seven studies
[14–16,18,20–22] reported the surface area exposed to laser that
ranged between 0.04 millimeter (mm)  to 1 cm. Number of laser ses-
sions ranged from one to 20 sessions and frequency of radiation
ranged from one to 5 sessions per week.
3.4. Main outcome of the studies
In all uncontrolled studies [15–18,20] a significant improvement
of BMS  symptoms that ranged from 47% to 80.4% was  reported. In
one controlled study, Arbabi Kalati et al. [19] reported a signifi-
cant improvement of BMS  symptoms among laser treated patients
compared with placebo group.
Spanemberg et al. [8] has evaluated the efficacy of Laser ther-
apy in treatment of BMS. A diode laser was  used in 78 patients,
randomly divided into 4 groups. one group (IR3W) received
infrared laser (wavelength 830 nm,  weekly session, 10 sessions);
one group (IR3W) received infrared laser (wavelength 830 nm, 1
session/week, 9 sessions; one group received red laser (685 nm,
35 mW,  2J, 72 J/cm, 3 session/week, 9 sessions), and control group
(placebo). The authors found that all groups have shown a signifi-
cant reduction in symptoms. Compared to the baseline scores, the
decrease in symptoms at the end of treatment was  67% in IR3W
group, 59.9% in the IR1W, 49% in the red laser group, and only
26.3% in the placebo group. The results showed significant differ-
ences between infrared laser groups and control group. Yet there
was no significant difference between the red laser group versus
the control group. The authors suggested a beneficial effect of laser
therapy when the appropriate wavelength is applied.
Pezlj-Ribaric et al. [21] evaluated the effect of laser on saliva
proinflammatory cytokines among 40 BMS  patients. The subjects
were randomly allocated into two  groups, Laser group and placebo
controls. The authors did not find significant differences in symp-
toms of BMS  between the two groups. However, the authors
found a significant decrease in the level of saliva proinflammatory
cytokines in favor of the laser group.
Ardunio et al. [14] treated 33 BMS  patients, randomly assigned
into two  groups: One group received laser (two sessions weekly for
5 weeks) while the other received a topical clonazepam therapy for
three weeks, (1 mg,  three times a day). The Laser group showed a
significant improvement in all pain parameters compared to the
clonazepam group. The authors concluded that LLL is superior to
Clonazepam in reducing BMS  symptoms
Sugaya et al. [22] evaluated the efficiency of LLl in treatment of
BMS  in 23 patients randomly allocated into two groups (Laser and
placebo). The results showed that the laser group as well as the
placebo group showed a significant improvement in the symptoms,
and that the laser group showed a statistically better improvement
only at the fourth checkpoint. The authors concluded that laser
therapy is as effective as placebo in treatment of BMS, suggesting
an emotional involvement in the symptomology of BMS.
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4. Discussion
LLLT has generated interest as an alternative treatment option in
BMS  as it is a non-invasive treatment with anti-inflammatory and
biostmulatory properties that accelerate wound healing. Hence,
this systematic review was envisioned to address a focused
research question related to the efficacy of LLLT in the treatment
of BMS. Analysis of the limited evidence available confirms that
LLLT was shown to be an effective treatment strategy for the man-
agement of BMS. However, the outcome of this systematic review
should be considered with caution owing to the varied method-
ologies and substantial variations in laser dosimetry among these
studies.
A key area of concern in LLLT is the lack of consensus related
to the laser parameters used by various researchers in their stud-
ies. The therapeutic effects of LLLT on the tissues are governed by
various factors such as wavelength of the laser, power output, spot
size, energy dose, application interval and irradiation frequency.
One among the key parameters is related to the laser dose. Despite
the various recommendations put forward by researchers, the ideal
dose remains a topic of controversy. Dosage guidelines for LLLT
from analysis of the literature suggest that an energy dose in the
range of 0.5–8 J/cm2 is ideal to reduce inflammation and acceler-
ate wound healing [25]. The studies included in the scope of this
review displayed a wide variation in the dose, with energy dose
per treatment point ranging from 0.4J–6 J reflecting a lack of unifor-
mity in the ideal dose of LLLT in the treatment of BMS. Furthermore,
the studies, which were included as part of this review displayed
substantial heterogeneity regarding the overall laser parameters,
with widespread variations in the wavelength (630–980m), power
output(20–300 mW),  energy dose per treatment point (0.4–6 J),
energy density of laser (0.53–176J/cm2), exposure time (10 s to
15 min) and frequency of laser sessions varying from 1 to 20. Hence,
a meta-analysis of these studies could not have been conducted due
to the diverse methodologies and absence of uniformity in laser
parameters. Though these studies [8,14–20] differed in the laser
parameters, they collectively showcased the efficacy of laser to
relieve symptoms associated with BMS. However, a lack of consen-
sus on the ideal laser parameters creates a barrier in establishment
of an ideal laser-based treatment protocol for BMS.
As per most research guidelines, it is mandatory to consider
a credible study methodology in order to investigate the efficacy
of any treatment approach. Therefore, it is imperative that the
superior efficacy of LLLT in reducing pain associated with BMS
can be assessed accurately only through the inclusion of a prop-
erly designed randomized trial with a placebo. Among the studies
included in the present systematic review, only a few studies
[8,19,21,22] complied and had a placebo arm in the study design.
The majority of the studies failed to include a placebo which would
have established the relative supremacy of LLLT and minimized the
risk of bias in the interpretation of the results.
The desired outcomes of LLLT in BMS  were to reduce the symp-
toms of pain and burning sensation. Of these two, reduction in pain
was chosen as the key outcome of LLLT. Among the various scales,
VAS is recognized as the most common sensitive scale for quanti-
tative evaluation of a subject’s pain and is accurate in assessment
of the effects of a treatment.
The majority of included studies [8,14–16,18–22] used VAS for
subjective assessment of pain. Some studies used different pain
scales, such as the Visual Numeric Scale [8], McGill pain ques-
tionnaire [14] and Numeric Rating scale [17]. Though most of the
studies applied VAS to evaluate pain bringing homogeneity and
reliability, comparison of the outcomes was  not possible owing to
the wide disparities in the data reporting practices for VAS scores
across these studies, as summarized in Table 2. The reduction of










































[28] B. Kalakonda, S. Farista, P. Koppolu, K. Baroudi, U. Uppada, A. Mishra, et al.,S.A. Al-Maweri et al. / Photodiagnosis an
rated by successful use of LLLT in various applications; recurrent
phthous stomatitis [26], temporomandibular joint disorders [12],
ral mucositis induced by cancer therapy [27]. The reduction in
ain and burning sensation by LLLT has been attributed to various
echanisms. The analgesic effect of LLLT is primarily due to release
f ß-endorphins and enkephalins, which are natural pain killers in
ur body and through decreased secretion of pain mediators like
radykinin and histamine. Pain relief is also attributed to a decrease
n the activity of C fibers and enhanced ATP synthesis thereby lead-
ng to reduction in pain stimuli conductance [14,19,28].
The present systematic review has certain limitations. Most of
he studies included in this review had a small sample size, cer-
ainly a shortcoming when a new treatment modality is assessed.
lso, there was inconsistency in data reporting of VAS scores among
ll the studies. Furthermore, a major limitation was a substantial
eterogeneity of the laser parameters among all the studies.
Further well designed randomized, double-blinded, placebo
ontrolled trial with adequate sample size are warranted to assess
he role of LLLT in the treatment of BMS. It is recommended that
deal laser parameters based on the analysis of the best available
vidence should be considered. Adequate measures should be taken
o control bias while reporting the outcome assessment.
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